We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Evolutec Grp | LSE:EVC | London | Ordinary Share | GB00B01JLR99 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 41.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMEVC
RNS Number : 4161R
AIM
29 April 2009
+----------------------------------------------------------------------------+
| ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN |
| ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") |
+----------------------------------------------------------------------------+
| |
+----------------------------------------------------------------------------+
| COMPANY NAME: |
+----------------------------------------------------------------------------+
| Evolutec Group plc |
| |
+----------------------------------------------------------------------------+
| COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING |
| ADDRESS (INCLUDING POSTCODES) : |
+----------------------------------------------------------------------------+
| 3 More London Riverside, London, SE1 2AQ |
| |
+----------------------------------------------------------------------------+
| COUNTRY OF INCORPORATION: |
+----------------------------------------------------------------------------+
| England & Wales |
| |
+----------------------------------------------------------------------------+
| COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE |
| 26: |
+----------------------------------------------------------------------------+
| www.evolutec.com |
| |
+----------------------------------------------------------------------------+
| COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF |
| AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY). IF THE |
| ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS |
| SHOULD BE STATED: |
+----------------------------------------------------------------------------+
| Evolutec Group plc ("Evolutec") is classed as an investment company under |
| the AIM Rules. The investment policy of Evolutes' has been to seek a |
| single investment, most probably of a UK or European business, in either |
| the technology, healthcare or service related sectors. |
| The main country of operation is England. |
| The boards of Evolutec and Nanoco Tech Public Limited Company ("Nanoco") |
| have reached agreement on the terms of recommended share acquisition by |
| Evolutec of the entire issued and to be issued share capital of Nanoco to |
| be effected by means of a court approved scheme of arrangement. |
| Admission is sought as a result of a reverse take-over under Rule 14. |
| Nanoco is a leading nanotechnology company involved in the development and |
| manufacture of fluorescent semi-conducting materials called quantum dots. |
| Quantum dots are a platform technology with uses in a wide range of |
| applications from life sciences through to optoeletronics dominated by |
| solid state lighting, photovoltaics and next generation displays. |
| Quantum dot based applications have the ability to potentially offer |
| significant benefits in performance and energy savings compared to those |
| materials currently used. |
| |
+----------------------------------------------------------------------------+
| DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO |
| TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, |
| nominal value and issue price to which it seeks admission and the number |
| and type to be held as treasury shares): |
+----------------------------------------------------------------------------+
| 184,088,032 Ordinary Shares of 10p each |
| |
+----------------------------------------------------------------------------+
| CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET |
| CAPITALISATION ON ADMISSION: |
+----------------------------------------------------------------------------+
| Anticipated market capitalisation upon admission - GBP69,033,012 |
| |
+----------------------------------------------------------------------------+
| PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: |
+----------------------------------------------------------------------------+
| 83.56% |
| |
+----------------------------------------------------------------------------+
| DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM |
| SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR |
| TRADED: |
+----------------------------------------------------------------------------+
| N/A |
| |
+----------------------------------------------------------------------------+
| FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining |
| the first name by which each is known or including any other name by which |
| each is known): |
+----------------------------------------------------------------------------+
| Directors |
| Dr. David Philip Bloxham - Non-Executive Chairman |
| Gordon James Hall - Non-Executive Director |
| Mark Barrie Hawtin - Non-Executive Director |
| Graeme Manson Hart - Non-Executive Director |
| Proposed Directors |
| Dr. Peter John Rowley - Non-Executive Chairman |
| Dr. Michael Albert Edelman - Chief Executive Officer |
| Dr. Nigel Leroy Pickett - Chief Technical Officer |
| Michael Anthony Bretherton - Chief Financial Officer |
| Upon Admission the board of the Company will comprise of the Proposed |
| Directors and Gordon James Hall. |
| |
+----------------------------------------------------------------------------+
| FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A |
| PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION |
| (underlining the first name by which each is known or including any other |
| name by which each is known): |
+----------------------------------------------------------------------------+
| Before Admission |
| Gartmore Investment Management Limited - 25.99% |
| Kisco Limited - 12.16% |
| Fortis Bank - 11.06% |
| GAM International - 10.87% |
| Close Asset Management - 5.07% |
| Charles Stanley - 4.24% |
| After Admission |
| ORA Guernsey - 36.34% |
| Gartmore - 16.10% |
| Mitsubishi UFJ - 6.45% |
| Nigel Pickett - 5.67% |
| Paul O'Brien - 5.39% |
| Michael Edelman - 5.03% |
| Manchester Tech Fund - 3.73% |
| Nora Powell - 3.26% |
| |
+----------------------------------------------------------------------------+
| NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, |
| PARAGRAPH (H) OF THE AIM RULES: |
+----------------------------------------------------------------------------+
| None |
| |
+----------------------------------------------------------------------------+
| * ANTICIPATED ACCOUNTING REFERENCE DATE * |
| DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS |
| BEEN PREPARED (this may be represented by unaudited interim financial |
| information)* |
| DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM |
| RULES 18 AND 19: |
+----------------------------------------------------------------------------+
| * 31 July* |
| Year ended 31 December 2008.* |
| 30 November 2009 (Annual Accounts) 30 April 2010 (Interims) 31 January |
| 2011 (Annual Report) |
| Note: The current accounting reference date is 31 December and will change |
| on Admission to 31 July. |
| |
+----------------------------------------------------------------------------+
| EXPECTED ADMISSION DATE: |
+----------------------------------------------------------------------------+
| 1 May 2009 |
| |
+----------------------------------------------------------------------------+
| NAME AND ADDRESS OF NOMINATED ADVISER: |
+----------------------------------------------------------------------------+
| Zeus Capital Limited |
| 3 Ralli Courts |
| West Riverside |
| Manchester |
| M3 5FT |
| |
+----------------------------------------------------------------------------+
| NAME AND ADDRESS OF BROKER: |
+----------------------------------------------------------------------------+
| Zeus Capital Limited |
| 3 Ralli Courts |
| West Riverside |
| Manchester |
| M3 5FT |
| |
+----------------------------------------------------------------------------+
| OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR |
| INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A |
| STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE |
| ADMISSION OF ITS SECURITIES: |
+----------------------------------------------------------------------------+
| The Admission document will be available from the following address and |
| will contain full details about the applicant and the admission of its |
| securities; |
| Zeus Capital Limited |
| 3 Ralli Courts |
| West Riverside |
| Manchester |
| M3 5FT |
| |
+----------------------------------------------------------------------------+
| DATE OF NOTIFICATION: |
+----------------------------------------------------------------------------+
| 29 April 2009 |
| |
+----------------------------------------------------------------------------+
| NEW/ UPDATE: |
+----------------------------------------------------------------------------+
| Update |
| |
+----------------------------------------------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
PAAUKVNRKORSUAR
1 Year Evolutec Chart |
1 Month Evolutec Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
